All In Biotech

Drug Trial Radar · NCT04345367

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Last checked: Nov 19, 2026Latest source record: Jul 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 727 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

727

Actual

Start

Jun 11, 2020

Primary completion

Jul 13, 2021

Study completion Jul 13, 2021

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg administered by subcutaneous injection every other week (as per label guidelines) in adult participants on background topical therapy, with moderate to severe AD. The treatment duration is 26 weeks. A total of approximately 600 participants will be enrolled from approximately 220 sites globally. Approximately 600 participants will be randomly assigned to study intervention. There are primary efficacy assessments at Week 2 and Week 4, and a key secondary efficacy assessment at Week 16. Efficacy and safety endpoints will be assessed throughout the entire study. Exploratory endpoints related to hand eczema efficacy will be assessed throughout the study.

Conditions

  • Atopic Dermatitis

Interventions

  • Abrocitinib 200 mgDrug

    Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.

  • Dupilumab 300 mgCombination product

    Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2Time frame: Week 2
  2. Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4Time frame: Week 4

Locations

151 sites in 15 countries. Site status is shown where the registry gives one.

  • Total Skin & Beauty Dermatology Center, PC

    Birmingham, Alabama

  • Clinical Research Center Of Alabama

    Birmingham, Alabama

  • Alliance Dermatology & MOHS Center, PC

    Phoenix, Arizona

  • First OC Dermatology

    Fountain Valley, California

  • Ark Clinical Research

    Long Beach, California

  • Beach Allergy and Asthma Specialty Group, A Medical Corporation

    Long Beach, California

  • Wallace Medical Group, Inc

    Los Angeles, California

  • Empire Clinical Research

    Pomona, California

  • MedDerm Associates

    San Diego, California

  • University of California San Diego Dermatology

    San Diego, California

  • University Clinical Trials Inc.

    San Diego, California

  • Synergy Dermatology

    San Francisco, California

  • Wolverine Clinical Trials, Llc

    Santa Ana, California

  • Clinical Science Institute

    Santa Monica, California

  • Skin Care Research, LLC

    Boca Raton, Florida

  • Olympian Clinical Research

    Largo, Florida

  • Miami Dermatology & Laser Research, LLC

    Miami, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Accel Research Sites - Pure Skin Dermatology & Aesthetics

    Orlando, Florida

  • Clinical Research Trials of Florida, Inc.

    Tampa, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • Integrated Clinical Research

    West Palm Beach, Florida

  • One Health Research Clinic

    Norcross, Georgia

  • Sneeze, Wheeze & Itch Associates, LLC

    Normal, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • The South Bend Clinic Center for Research

    South Bend, Indiana

  • Epiphany Dermatology of Kansas, LLC

    Overland Park, Kansas

  • Avant Research Associates, LLC

    Crowley, Louisiana

  • MetroBoston Clinical Partners, LLC

    Brighton, Massachusetts

  • Onyx Clinical Research

    Flint, Michigan

  • Linden Road Imaging Center

    Flint, Michigan

  • Hamzavi Dermatology

    Fort Gratiot, Michigan

  • Regional Medical Imaging, P.C. ( Local X-Ray)

    Royal Oak, Michigan

  • Revival Research Institute, LLC

    Troy, Michigan

  • Skin Specialists, PC

    Omaha, Nebraska

  • Vivida Dermatology

    Las Vegas, Nevada

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

  • Boice-Willis Clinic, PA

    Rocky Mount, North Carolina

  • Carolina Research Center, Inc.

    Shelby, North Carolina

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.